Evaluation of Drivers of Treatment Switch in Relapsing Multiple Sclerosis: a Study from the Italian MS Registry

Background: Active relapsing-remitting (RR) and secondary progressive (SP) multiple sclerosis (MS) are currently defined as "relapsing MS" (RMS). The aim of this cross-sectional study was to assess drivers of treatment switches due to clinical relapses in a population of RMS patients collected in the Italian MS and Related Disorders Register (I-MS&RD).

Methods: RRMS and SPMS patients with at least one relapse in a time window of 2 years before of data extraction were defined as RMS. Factors associated with disease-modifying therapy (DMT) switching due to clinical activity were assessed through multivariable logistic regression models in which treatment exposure was included as the last recorded DMT and the last DMT's class [moderate-efficacy (ME), high-efficacy (HE) DMTs and anti-CD20 drugs].

Results: A cohort of 4739 RMS patients (4161 RRMS, 578 SPMS) was extracted from the I-MS&RD. A total of 2694 patients switching DMTs due to relapses were identified. Switchers were significantly (p < 0.0001) younger, less disabled, more frequently affected by an RR disease course in comparison to non-switcher patients. The multivariable logistic regression models showed that Alemtuzumab (OR 0.08, 95% CI 0.02-0.37), Natalizumab (0.48, 0.30-0.76), Ocrelizumab (0.1, 0.02-0.45) and Rituximab (0.23, 0.06-0.82) exposure was a protective factor against treatment switch due to relapses. Moreover, the use of HE DMTs (0.43, 0.31-0.59), especially anti-CD20 drugs (0.14, 0.05-0.37), resulted to be a protective factor against treatment switch due to relapses in comparison with ME DMTs.

Conclusions: More than 50% of RMS switched therapy due to disease activity. HE DMTs, especially anti-CD20 drugs, significantly reduce the risk of treatment switch.

References

Filippi M, Danesi R, Derfuss T, Duddy M, Gallo P, Gold R . Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2021; 269(3):1670-1677. PMC: 8501364. DOI: 10.1007/s00415-021-10836-8. View

Bayas A, Berthele A, Blank N, Dreger P, Faissner S, Friese M . Autologous haematopoietic stem cell transplantation for multiple sclerosis: a position paper and registry outline. Ther Adv Neurol Disord. 2023; 16:17562864231180730. PMC: 10540601. DOI: 10.1177/17562864231180730. View

Gross R, Corboy J . Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019; 25(3):715-735. DOI: 10.1212/CON.0000000000000738. View

Ziemssen T, Derfuss T, De Stefano N, Giovannoni G, Palavra F, Tomic D . Optimizing treatment success in multiple sclerosis. J Neurol. 2015; 263(6):1053-65. PMC: 4893374. DOI: 10.1007/s00415-015-7986-y. View

He A, Merkel B, Brown J, Zhovits Ryerson L, Kister I, Malpas C . Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020; 19(4):307-316. DOI: 10.1016/S1474-4422(20)30067-3. View

Harding K, Williams O, Willis M, Hrastelj J, Rimmer A, Joseph F . Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis. JAMA Neurol. 2019; 76(5):536-541. PMC: 6515582. DOI: 10.1001/jamaneurol.2018.4905. View

Merkel B, Butzkueven H, Traboulsee A, Havrdova E, Kalincik T . Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmun Rev. 2017; 16(6):658-665. DOI: 10.1016/j.autrev.2017.04.010. View

Hauser S, Cree B . Treatment of Multiple Sclerosis: A Review. Am J Med. 2020; 133(12):1380-1390.e2. PMC: 7704606. DOI: 10.1016/j.amjmed.2020.05.049. View

Iaffaldano P, Lucisano G, Butzkueven H, Hillert J, Hyde R, Koch-Henriksen N . Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Mult Scler. 2021; 27(10):1543-1555. DOI: 10.1177/13524585211010128. View

10.

Trojano M, Bergamaschi R, Amato M, Comi G, Ghezzi A, Lepore V . The Italian multiple sclerosis register. Neurol Sci. 2018; 40(1):155-165. PMC: 6329744. DOI: 10.1007/s10072-018-3610-0. View

11.

Magyari M, Joensen H, Laursen B, Koch-Henriksen N . The Danish Multiple Sclerosis Registry. Brain Behav. 2020; 11(1):e01921. PMC: 7821574. DOI: 10.1002/brb3.1921. View

12.

Trojano M, Kalincik T, Iaffaldano P, Amato M . Interrogating large multiple sclerosis registries and databases: what information can be gained?. Curr Opin Neurol. 2022; 35(3):271-277. DOI: 10.1097/WCO.0000000000001057. View

13.

Lorscheider J, Buzzard K, Jokubaitis V, Spelman T, Havrdova E, Horakova D . Defining secondary progressive multiple sclerosis. Brain. 2016; 139(Pt 9):2395-405. DOI: 10.1093/brain/aww173. View

14.

Iaffaldano P, Lucisano G, Patti F, Morra V, De Luca G, Lugaresi A . Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. Mult Scler. 2020; 27(3):430-438. DOI: 10.1177/1352458520974366. View

15.

Scott T, Diehl D, Elmalik W, Gettings E, Hackett C, Schramke C . Multiple sclerosis relapses contribute to long-term disability. Acta Neurol Scand. 2019; 140(5):336-341. DOI: 10.1111/ane.13149. View

16.

Jokubaitis V, Spelman T, Kalincik T, Lorscheider J, Havrdova E, Horakova D . Predictors of long-term disability accrual in relapse-onset multiple sclerosis. Ann Neurol. 2016; 80(1):89-100. DOI: 10.1002/ana.24682. View

17.

Lublin F, Haring D, Ganjgahi H, Ocampo A, Hatami F, cuklina J . How patients with multiple sclerosis acquire disability. Brain. 2022; 145(9):3147-3161. PMC: 9536294. DOI: 10.1093/brain/awac016. View

18.

Rotstein D, Montalban X . Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019; 15(5):287-300. DOI: 10.1038/s41582-019-0170-8. View

19.

Montalban X, Gold R, Thompson A, Otero-Romero S, Amato M, Chandraratna D . ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018; 24(2):96-120. DOI: 10.1177/1352458517751049. View

20.

Rae-Grant A, Day G, Marrie R, Rabinstein A, Cree B, Gronseth G . Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90(17):777-788. DOI: 10.1212/WNL.0000000000005347. View